AliveCor is ranked #1 Most Innovative Company in Artificial Intelligence by Fast Company
To produce its 2018 list,Fast Co...
AliveCor, Inc has been ranked the number one company utilising artificial intelligence within the healthcare industry.
To produce its 2018 list, Fast Company has surveyed thousands of enterprises across the globe to identify the most notable innovations of the year and trace the impact of those initiatives on business, industry, and the larger culture.
Ranked third out of the health category last year, its move to the number one position in the AI category highlights how its FDA-cleared machine learning techniques have provided proactive heart and cardiac care across a number of technologies.
The company also ranked 20th overall in an evaluation of thousands of companies worldwide in Fast Company's Top 50 Most Innovative Companies in the World.
- Beyond electronic medical records: Healthcare's second wave of digitisation
- Healthcare leading the way in data security awareness
- The UAE is set to launch its first Medical Sector Summit, based on AI
The FDA-cleared KardiaMobile is the most clinically validated mobile EKG solution on the market. It is recommended by leading cardiologists and used by people worldwide for accurate ECG recordings. KardiaMobile, and KardiaBand, when paired with the Kardia app provide instant analysis for detecting atrial fibrillation (AF) and normal sinus rhythm in an ECG.
Kardia is the first AI enabled platform to help clinicians manage patients for the early detection of atrial fibrillation, the most common cardiac arrhythmia and one that leads to a five times greater risk of stroke. KardiaBand is the first FDA-cleared medical device accessory for Apple Watch Series 1,2 and 3, which will support the detection of abnormal heart murmurs through the use of electrode sensors.
Utilising AI, cloud and micro-electrode technology to advance the state of the art in cardiac care, AliveCor empowers people to proactively manage heart health and improve the quality of care in the fight against heart disease. Its deep neural network assesses heart rate data, as well as physical activity and other influencing factors, to help patients develop deeper insights into their heart rhythm.
Over time, AliveCor's analysis of biometric data will work to evaluate a range of serious heart conditions and even changes in blood chemistry through AI software, SmartRhythm. The use of AI will help add meaning to patient data, and facilitate important improvements in insights, therapies, and procedures.
NHS opens 8 clinical trial sites to assess cancer treatment
The UK's National Health Service (NHS) is opening eight clinical trial sites to assess patients' responses to personalised cancer therapy.
The trials will analyse how patients diagnosed with advanced melanoma or non-small cell lung cancer respond to immunotherapy, to help predict their response to treatment. They will be hosted at Gloucestershire Hospitals NHS Foundation Trust facilities.
Immunotherapy helps the body's own immune system fight cancer, but while it has achieved good results for some cancer patients, it is not successful for everyone. Finding ways to predict which people will respond to the treatment is a major area of research.
OncoHost, an oncology startup, will provide advanced machine learning technology to develop personalised strategies aiming to improve the success rate of the cancer therapy. The trials will contribute to OncoHost’s ongoing PROPHETIC study, which uses the company’s host response profiling platform, PROphet®.
“Immunotherapy has achieved excellent results in certain situations for several cancers, allowing patients to achieve longer control of their cancer with maintained quality of life and longer survival,” said Dr David Farrugia, Consultant Medical Oncologist at NHS, and chief investigator of all eight NHS clinical trial sites.
“However, success with immunotherapy is not guaranteed in every patient, so this PROPHETIC study is seeking to identify changes in proteins circulating in the blood which may help doctors to choose the best treatment for each patient."
"I am excited that Gloucestershire Oncology Centre and its research department have this opportunity to contribute to this growing field of research and I am determined that our centre will make a leading national contribution in patient recruitment.”
Previous studies in the US and Israel have shown that PROphet® has high accuracy in predicting how patients with cancer will respond to various therapies.